Matthew Hawryluk is Director of Predictive Oncology Inc.. Currently has a direct ownership of 9,488 shares of POAI, which is worth approximately $7,021. The most recent transaction as insider was on Apr 05, 2024, when has been sold 2,368 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 9.49K
0% 3M change
32.98% 12M change
Total Value Held $7,021

Matthew Hawryluk Transaction History

Date Transaction Value Shares Traded Shares Held Form
Apr 05 2024
BUY
Grant, award, or other acquisition
-
2,368 Added 19.97%
9,488 Common Stock
Oct 02 2023
BUY
Grant, award, or other acquisition
-
1,875 Added 20.81%
7,135 Common Stock
Jul 03 2023
BUY
Grant, award, or other acquisition
-
2,675 Added 33.71%
5,260 Common Stock
Apr 03 2023
BUY
Grant, award, or other acquisition
-
18,360 Added 26.21%
51,692 Common Stock
Jan 03 2023
BUY
Grant, award, or other acquisition
-
19,570 Added 36.99%
33,332 Common Stock
Dec 01 2022
BUY
Grant, award, or other acquisition
-
13,762 Added 50.0%
13,762 Common Stock

Also insider at

GRTS
Gritstone bio, Inc. Healthcare
MH

Matthew Hawryluk

Director
Emeryville, CA

Track Institutional and Insider Activities on POAI

Follow Predictive Oncology Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells POAI shares.

Notify only if

Insider Trading

Get notified when an Predictive Oncology Inc. insider buys or sells POAI shares.

Notify only if

News

Receive news related to Predictive Oncology Inc.

Track Activities on POAI